CSIMarket Company Name, Ticker, Industry, else..
 
Ispecimen inc   (NASDAQ: ISPC)
Other Ticker:  
 
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare
 
Price: $3.4800 $-0.49 -12.343%
Day's High: $4 Week Perf: -13.43 %
Day's Low: $ 3.44 30 Day Perf: -23.52 %
Volume (M): 104 52 Wk High: $ 12.20
Volume (M$): $ 361 52 Wk Avg: $6.47
Open: $3.94 52 Wk Low: $3.41



 Market Capitalization (Millions $) 2
 Shares Outstanding (Millions) 1
 Employees 145
 Revenues (TTM) (Millions $) 10
 Net Income (TTM) (Millions $) -10
 Cash Flow (TTM) (Millions $) -1
 Capital Exp. (TTM) (Millions $) 2

Ispecimen Inc
Ispecimen Inc. is a technology company that specializes in providing biospecimen supply and data services to the healthcare and life sciences industries. They have developed a unique platform that enables researchers and drug developers to access and obtain high-quality human biospecimens for their research and development activities. These specimens include blood, tissue, and other biological materials, which are crucial for advancing medical breakthroughs and improving patient care. Ispecimen Inc. also offers data services, where they aggregate and standardize clinical and research data to create valuable insights for their clients. By connecting healthcare providers, patients, and researchers, Ispecimen Inc. aims to accelerate the pace of medical research and ultimately contribute to better diagnostics, treatments, and cures for various diseases.


   Company Address: 8 Cabot Road, Woburn, 1801 MA
   Company Phone Number: 301-6700   Stock Exchange / Ticker: NASDAQ ISPC


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
DGX   -0.35%    
FLGT        2.18% 
LH   -0.35%    
NTRA   -0.35%    
RDNT        1.81% 
XGN        15.61% 
• View Complete Report
   



Management Announcement

iSpecimen Inc Charts a Promising Financial Course: Recent Public Offering and Strategic Developments Indicate Growth and Stability

Published Thu, Oct 31 2024 7:08 PM UTC

iSpecimen Inc. Charts a Promising Financial Course: Recent Public Offering and Strategic Developments Indicate Growth and StabilityiSpecimen Inc. Charts a Promising Financial Course: Recent Public Offering and Strategic Developments Indicate Growth and StabilityIn a significant development for investors and stakeholders alike, iSpecimen Inc. (Nasdaq: ISPC) has successfully c...
Financing Agreement

iSpecimen Inc Secures $1 Million Loan and Strengthens Leadership Amid Strategic Growth Initiatives

Published Thu, Sep 26 2024 11:30 AM UTC

iSpecimen Inc. Secures $1 Million Loan and Strengthens Leadership Amid Strategic Growth InitiativesIntroductionOn September 26, 2024, iSpecimen Inc. (Nasdaq: ISPC), a recognized player in the global marketplace for biospecimens, proudly announced the securing of a $1 million loan agreement. This financial boost accompanies the appointment of three new members to its Board of...
Shares

iSpecimen Announces 1-for-20 Reverse Stock Split

Published Wed, Sep 11 2024 8:30 PM UTC



iSpecimen Announces 1-for-20 Reverse Stock Split Amid Growth Ambitions: Prepares to Share Full Year 2023 Financial Results
nnWOBURN, Mass., Sept. 11, 2024nn iSpecimen Inc. (Nasdaq: ISPC), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced pivotal news to...
Ispecimen Inc

iSpecimen Inc. Reports 76% Revenue Surge and Significant Loss Reduction, Signaling Positive Shift for Investors in Q2 2024

iSpecimen Inc. Reports Impressive Revenue Growth: A Bullish Outlook for Investors
In its fiscal span closing June 30, 2024, iSpecimen Inc. (Nasdaq: ISPC) reported an astounding 76.21% revenue growth, reaching approximately $2.86 million. This remarkable surge is not only impressive by itself but also stands out in comparison to the broader Medical Laboratories industry, which saw average growth of just 0.40% during the same period. With a commitment to connecting scientists with essential healthcare specimens, iSpecimen's latest financial results signal a turning point that could reshape its trajectory and appeal to investors.
One of the biggest highlights of iSpecimen's recent performance is the substantial reduction in losses. The company's earnings per share (EPS) improved to a loss of $-0.19 per share from $-0.39 in the comparable reporting period last year. Such an improvement reflects iSpecimen's solid operational management and strategic focus, highlighting its ability to scale its innovative platform effectively. Notably, the firm also posted a net shortfall of $-2.109 million, a substantial decrease from a loss of $-3.484 million in the year-ago quarter. This reduction in losses further emphasizes the potential for profitability as iSpecimen continues to grow and optimize its services.
Ispecimen Inc

Medical Laboratories company reports significant loss in financial period ending March 31, 2024

As a Wall Street journalist, it is interesting to analyze the latest financial results of iSpecimen Inc, a company operating in the Medical Laboratories industry. The company reported a net deficit per share of $-0.32 for the financial period ending March 31, 2024, which was higher than the previous year. Additionally, revenue fell by -22.378% to $2.29 million, showcasing a decline in performance compared to the same period the year before.
Despite the company's weak financial performance, it is important to note that the overall Medical Laboratories industry recorded a 1.91% growth in revenue during the first quarter of 2024 compared to the same period a year ago. This indicates that iSpecimen Inc is facing challenges within its specific market segment, and may need to strategize and innovate in order to improve its financial standing.






Ispecimen Inc's Segments
Specimens    98.68 % of total Revenue
Shipping and other    1.32 % of total Revenue





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com